← All trials

NCT07227402

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Dec 29, 2025
Primary completion
Feb 27, 2032
Completion date
Feb 27, 2032
First posted
Nov 12, 2025
Last posted
Nov 12, 2025
Enrollment
904
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.